

Grant S Stewart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8707516/publications.pdf>

Version: 2024-02-01

164
papers

7,001
citations

81900

39
h-index

74163

75
g-index

174
all docs

174
docs citations

174
times ranked

12077
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	670
2	Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. <i>Science</i> , 2018, 361, 594-599.	12.6	511
3	Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal. <i>Cell</i> , 2018, 173, 611-623.e17.	28.9	398
4	Spatiotemporal immune zonation of the human kidney. <i>Science</i> , 2019, 365, 1461-1466.	12.6	281
5	Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study. <i>Journal of Urology</i> , 2013, 189, 1110-1116.	0.4	200
6	Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. <i>BJU International</i> , 2012, 110, 614-628.	2.5	197
7	Epidemiology and screening for renal cancer. <i>World Journal of Urology</i> , 2018, 36, 1341-1353.	2.2	183
8	Prognostic factors and prognostic models for renal cell carcinoma: a literature review. <i>World Journal of Urology</i> , 2018, 36, 1943-1952.	2.2	162
9	PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. <i>Nature Communications</i> , 2018, 9, 746.	12.8	156
10	Pathophysiology of cancer cachexia: Much more than host-tumour interaction?. <i>Clinical Nutrition</i> , 2007, 26, 667-676.	5.0	153
11	BOD1L Is Required to Suppress Deleterious Resection of Stressed Replication Forks. <i>Molecular Cell</i> , 2015, 59, 462-477.	9.7	146
12	ctDNA monitoring using patient-specific sequencing and integration of variant reads. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	116
13	Oncometabolites in renal cancer. <i>Nature Reviews Nephrology</i> , 2020, 16, 156-172.	9.6	113
14	Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. <i>BJU International</i> , 2012, 110, 1608-1617.	2.5	111
15	Radiomics of computed tomography and magnetic resonance imaging in renal cell carcinoma—a systematic review and meta-analysis. <i>European Radiology</i> , 2020, 30, 3558-3566.	4.5	106
16	Identification of the First ATRIP-Deficient Patient and Novel Mutations in ATR Define a Clinical Spectrum for ATRIP Seckel Syndrome. <i>PLoS Genetics</i> , 2012, 8, e1002945.	3.5	104
17	A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. <i>BJU International</i> , 2005, 95, 791-793.	2.5	101
18	Embryonal precursors of Wilms tumor. <i>Science</i> , 2019, 366, 1247-1251.	12.6	101

#	ARTICLE	IF	CITATIONS
19	Cancer cachexia and fatigue. <i>Clinical Medicine</i> , 2006, 6, 140-143.	1.9	96
20	The relevance of a hypoxic tumour microenvironment in prostate cancer. <i>BJU International</i> , 2010, 105, 8-13.	2.5	94
21	Mutations in <i>DONSON</i> disrupt replication fork stability and cause microcephalic dwarfism. <i>Nature Genetics</i> , 2017, 49, 537-549.	21.4	81
22	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. <i>European Urology</i> , 2019, 76, 754-764.	1.9	80
23	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4064-4075.	1.6	78
24	Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. <i>Prostate</i> , 2016, 76, 1078-1087.	2.3	74
25	TRAIP promotes DNA damage response during genome replication and is mutated in primordial dwarfism. <i>Nature Genetics</i> , 2016, 48, 36-43.	21.4	74
26	Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. <i>Oncology Reports</i> , 2008, 20, 1561-7.	2.6	74
27	Mutations in the NHEJ Component XRCC4 Cause Primordial Dwarfism. <i>American Journal of Human Genetics</i> , 2015, 96, 412-424.	6.2	71
28	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. <i>European Urology Focus</i> , 2019, 5, 857-866.	3.1	67
29	What can molecular pathology contribute to the management of renal cell carcinoma?. <i>Nature Reviews Urology</i> , 2011, 8, 255-265.	3.8	66
30	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020, 12, 23.	8.2	66
31	Endoscopic Versus Laparoscopic Management of Noninvasive Upper Tract Urothelial Carcinoma: 20-Year Single Center Experience. <i>Journal of Urology</i> , 2013, 189, 2054-2061.	0.4	65
32	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 6924-6934.	7.0	62
33	Elasticity as a biomarker for prostate cancer: a systematic review. <i>BJU International</i> , 2014, 113, 523-534.	2.5	62
34	A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma. <i>Nature Communications</i> , 2019, 10, 1152.	12.8	60
35	Preclinical Evaluation of the Versius Surgical System, a New Robot-assisted Surgical Device for Use in Minimal Access Renal and Prostate Surgery. <i>European Urology Focus</i> , 2021, 7, 444-452.	3.1	58
36	Quantitative diagnostics of soft tissue through viscoelastic characterization using time-based instrumented palpation. <i>Journal of the Mechanical Behavior of Biomedical Materials</i> , 2015, 41, 149-160.	3.1	56

#	ARTICLE	IF	CITATIONS
37	Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. <i>BMJ Open</i> , 2020, 10, e035938.	1.9	54
38	Is There a Human Homologue to the Murine Proteolysis-Inducing Factor?. <i>Clinical Cancer Research</i> , 2007, 13, 4984-4992.	7.0	47
39	Long-Term Comparative Outcomes of Open Versus Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial-Cell Carcinoma After a Median Follow-Up of 13 Years. <i>Journal of Endourology</i> , 2011, 25, 1329-1335.	2.1	43
40	NF- κ B-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis. <i>Cancer Discovery</i> , 2018, 8, 850-865.	9.4	41
41	Current evidence on screening for renal cancer. <i>Nature Reviews Urology</i> , 2020, 17, 637-642.	3.8	41
42	NO α -sulindac inhibits the hypoxia response of PCa prostate cancer cells via the Akt signalling pathway. <i>International Journal of Cancer</i> , 2009, 124, 223-232.	5.1	39
43	Surgical service centralisation in Australia versus choice and quality of life for rural patients. <i>Medical Journal of Australia</i> , 2006, 185, 162-163.	1.7	38
44	Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2014, 66, 956-963.	1.9	38
45	DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions. <i>Biochemical Pharmacology</i> , 2011, 81, 203-210.	4.4	37
46	Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4013-4022.	3.6	35
47	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4212-4223.	7.0	33
48	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery—Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021, 4, 473-482.	5.4	33
49	Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 22-41.	5.4	33
50	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021, 108, 106482.	1.8	33
51	A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003489.	8.4	33
52	Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia. <i>Prostate</i> , 2007, 67, 1308-1317.	2.3	32
53	Genomics and clinical correlates of renal cell carcinoma. <i>World Journal of Urology</i> , 2018, 36, 1899-1911.	2.2	32
54	The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. <i>BMC Medicine</i> , 2019, 17, 182.	5.5	30

#	ARTICLE	IF	CITATIONS
55	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). <i>European Urology</i> , 2019, 75, 261-264.	1.9	30
56	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e92-e99.	1.9	30
57	Differential Expression of Prognostic Proteomic Markers in Primary Tumour, Venous Tumour Thrombus and Metastatic Renal Cell Cancer Tissue and Correlation with Patient Outcome. <i>PLoS ONE</i> , 2013, 8, e60483.	2.5	30
58	A Critical Analysis of the Learning Curve and Postlearning Curve Outcomes of Two Experience- and Volume-Matched Surgeons for Laparoscopic and Robot-Assisted Radical Prostatectomy. <i>Journal of Endourology</i> , 2015, 29, 939-947.	2.1	27
59	A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma. <i>BMC Cancer</i> , 2017, 17, 9.	2.6	27
60	Bi-allelic Variants in TONSL Cause SPONASTRIME Dysplasia and a Spectrum of Skeletal Dysplasia Phenotypes. <i>American Journal of Human Genetics</i> , 2019, 104, 422-438.	6.2	27
61	Single cell derived mRNA signals across human kidney tumors. <i>Nature Communications</i> , 2021, 12, 3896.	12.8	27
62	DONSON and FANCM associate with different replisomes distinguished by replication timing and chromatin domain. <i>Nature Communications</i> , 2020, 11, 3951.	12.8	26
63	Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor- α -targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020, 3, 168-173.	5.4	25
64	What are the Oncological Risks of Minimal Access Surgery for the Treatment of Urinary Tract Cancer?. <i>European Urology</i> , 2004, 46, 415-420.	1.9	24
65	Contemporary practice and technique-related outcomes for radical prostatectomy in the <sc>UK</sc>: a report of national outcomes. <i>BJU International</i> , 2015, 115, 753-763.	2.5	24
66	Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. <i>World Journal of Urology</i> , 2018, 36, 417-425.	2.2	24
67	The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. <i>Nature</i> , 2022, 606, 999-1006.	27.8	24
68	Targeted SERS nanosensors measure physicochemical gradients and free energy changes in live 3D tumor spheroids. <i>Nanoscale</i> , 2016, 8, 16710-16718.	5.6	23
69	Quality of life outcomes in patients with localised renal cancer: a literature review. <i>World Journal of Urology</i> , 2018, 36, 1961-1972.	2.2	23
70	Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. <i>European Urology Focus</i> , 2020, 6, 991-998.	3.1	23
71	The Use of Automated Quantitative Analysis to Evaluate Epithelial-to-Mesenchymal Transition Associated Proteins in Clear Cell Renal Cell Carcinoma. <i>PLoS ONE</i> , 2012, 7, e31557.	2.5	22
72	The operative safety and oncological outcomes of laparoscopic nephrectomy for T3 renal cell cancer. <i>BJU International</i> , 2012, 110, 884-890.	2.5	22

#	ARTICLE	IF	CITATIONS
73	Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e17-167.e23.	1.6	22
74	Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. <i>European Urology</i> , 2017, 71, 845-847.	1.9	22
75	Risk Prediction Models for Kidney Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 1380-1390.	3.1	22
76	The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2008, 11, 208-213.	2.5	21
77	The continuing medical education activities and attitudes of Australian doctors working in different clinical specialties and practice locations. <i>Australian Health Review</i> , 2009, 33, 47.	1.1	21
78	Reduction of pro-tumorigenic activity of human prostate cancer-associated fibroblasts using Dlk1 or SCUBE1. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 530-6.	2.4	20
79	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group's study. <i>European Journal of Cancer</i> , 2017, 80, 55-62.	2.8	18
80	Hyperpolarized ¹³ C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma—A Proof of Principle Study. <i>Cancers</i> , 2022, 14, 335.	3.7	18
81	Current Status of Focal Cryoablation for Small Renal Masses. <i>Urology</i> , 2016, 90, 9-15.	1.0	17
82	Consultation audio-recording reduces long-term decision regret after prostate cancer treatment: A non-randomised comparative cohort study. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2016, 14, 308-314.	1.8	17
83	A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). <i>British Journal of Cancer</i> , 2022, 127, 1051-1060.	6.4	17
84	Description and Validation of a Modular Training System for Laparoscopic Nephrectomy. <i>Journal of Endourology</i> , 2012, 26, 1512-1517.	2.1	16
85	Hypomorphic Mutations in TONSL Cause SPONASTRIME Dysplasia. <i>American Journal of Human Genetics</i> , 2019, 104, 439-453.	6.2	16
86	A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy: Development and Multinational Validation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1107-1117.	6.1	16
87	Functional and oncological outcomes of men under 60 years of age having endoscopic surgery for prostate cancer are optimal following intrafascial endoscopic extraperitoneal radical prostatectomy. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2011, 9, 65-71.	1.8	15
88	Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. <i>Cancers</i> , 2016, 8, 77.	3.7	15
89	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019, 53, 14-20.	1.0	15
90	Acceptability and potential impact on uptake of using different risk stratification approaches to determine eligibility for screening: A population-based survey. <i>Health Expectations</i> , 2021, 24, 341-351.	2.6	15

#	ARTICLE	IF	CITATIONS
91	Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. <i>International Journal of Oncology</i> , 2010, 36, 973-82.	3.3	14
92	Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials. <i>Nature Reviews Urology</i> , 2017, 14, 753-759.	3.8	14
93	Dynamic epigenetic changes to <i>VHL</i> occur with sunitinib in metastatic clear cell renal cancer. <i>Oncotarget</i> , 2016, 7, 25241-25250.	1.8	14
94	The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. <i>BMC Cancer</i> , 2022, 22, 99.	2.6	14
95	Five-year oncological outcomes of endoscopic extraperitoneal radical prostatectomy (<sc>EERPE</sc>) for prostate cancer: results from a medium-volume <sc>UK</sc> centre. <i>BJU International</i> , 2014, 113, 449-457.	2.5	12
96	Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?. <i>European Urology Focus</i> , 2018, 4, 972-977.	3.1	12
97	Setting Research Priorities in Partnership with Patients to Provide Patient-centred Urological Cancer Care. <i>European Urology</i> , 2019, 75, 891-893.	1.9	12
98	UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. <i>Urology</i> , 2020, 136, 162-168.	1.0	12
99	A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound. <i>European Urology Focus</i> , 2021, 7, 407-419.	3.1	12
100	Identifying opportunities for timely diagnosis of bladder and renal cancer via abnormal blood tests: a longitudinal linked data study. <i>British Journal of General Practice</i> , 2022, 72, e19-e25.	1.4	12
101	Risk models for recurrence and survival after kidney cancer: a systematic review. <i>BJU International</i> , 2022, 130, 562-579.	2.5	12
102	A Novel Bovine Model for Training Urological Surgeons in Laparoscopic Radical Nephrectomy. <i>Journal of Endourology</i> , 2011, 25, 1377-1383.	2.1	11
103	Renal cell carcinoma: standards and controversies. <i>World Journal of Urology</i> , 2018, 36, 1889-1890.	2.2	11
104	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. <i>BMJ Open</i> , 2020, 10, e044566.	1.9	11
105	The influence of hypoxia on the prostate cancer proteome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 980-993.	2.3	11
106	Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy. <i>BJU International</i> , 2022, 129, 290-303.	2.5	11
107	A community jury study exploring the public acceptability of using risk stratification to determine eligibility for cancer screening. <i>Health Expectations</i> , 2022, 25, 1789-1806.	2.6	11
108	Matched-Pair Analysis of Open versus Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Cell Carcinoma. <i>Urologia Internationalis</i> , 2015, 94, 156-162.	1.3	10

#	ARTICLE	IF	CITATIONS
109	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2018, 36, 1973-1980.	2.2	10
110	Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma. JCO Precision Oncology, 2020, 4, 1141-1151.	3.0	10
111	Tissue Quality Assessment Using a Novel Direct Elasticity Assessment Device (The E-Finger): A Cadaveric Study of Prostatectomy Dissection. PLoS ONE, 2014, 9, e112872.	2.5	9
112	Public attitudes towards screening for kidney cancer: an online survey. BMC Urology, 2020, 20, 170.	1.4	9
113	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Journal of Clinical Oncology, 2022, 40, 1772-1782.	1.6	9
114	The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers. Journal of Visualized Experiments, 2013, , .	0.3	8
115	Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Medicine, 2017, 15, 118.	5.5	8
116	Three-Dimensional Printed Molds for Image-Guided Surgical Biopsies: An Open Source Computational Platform. JCO Clinical Cancer Informatics, 2020, 4, 736-748.	2.1	8
117	The Management of Acute Urinary Retention: Treating the Curse of the Aging Male. Current Bladder Dysfunction Reports, 2013, 8, 242-249.	0.5	7
118	Quantitative mechanical assessment of the whole prostate gland ex vivo using dynamic instrumented palpation. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2017, 231, 1081-1100.	1.8	7
119	The Anorexia-Cachexia Syndrome. , 2009, , 587-595.		7
120	Proteolysis-inducing factor core peptide mediates dermcidin-induced proliferation of hepatic cells through multiple signalling networks. International Journal of Oncology, 2011, 39, 709-18.	3.3	6
121	Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature. International Urology and Nephrology, 2011, 43, 961-967.	1.4	6
122	A Generation of Laparoscopic Nephrectomy: Stage-Specific Surgical and Oncologic Outcomes for Laparoscopic Nephrectomy in a Single Center. Journal of Endourology, 2013, 27, 1008-1014.	2.1	6
123	Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 438.e11-438.e21.	1.6	6
124	The current state of genetic risk models for the development of kidney cancer: a review and validation. BJU International, 2022, 130, 550-561.	2.5	6
125	Patient specific modeling of palpation-based prostate cancer diagnosis: effects of pelvic cavity anatomy and intrabladder pressure. International Journal for Numerical Methods in Biomedical Engineering, 2016, 32, e02734.	2.1	5
126	Immunotherapy for Renal Cancer: Sequencing and Combinations. European Urology Focus, 2016, 2, 582-588.	3.1	5

#	ARTICLE	IF	CITATIONS
127	A novel method for rapid and quantitative mechanical assessment of soft tissue for diagnostic purposes: A computational study. International Journal for Numerical Methods in Biomedical Engineering, 2018, 34, e2917.	2.1	5
128	Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. World Journal of Urology, 2021, 39, 3377-3383.	2.2	5
129	Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?. BJU International, 2021, 128, 386-394.	2.5	5
130	Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. BJU International, 2022, 130, 244-253.	2.5	5
131	The burden of performing minimal access surgery: ergonomics survey results from 462 surgeons across Germany, the UK and the USA. Journal of Robotic Surgery, 2022, 16, 1347-1354.	1.8	5
132	The Molecular Biology of Renal Cancer: Another Piece of the Puzzle. European Urology, 2014, 66, 85-86.	1.9	4
133	Reasons for intending to accept or decline kidney cancer screening: thematic analysis of free text from an online survey. BMJ Open, 2021, 11, e044961.	1.9	4
134	Validation and public health modelling of risk prediction models for kidney cancer using the UK Biobank. BJU International, 2022, 129, 498-511.	2.5	4
135	Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma. PLoS ONE, 2021, 16, e0258988.	2.5	4
136	The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol. BMC Cancer, 2021, 21, 1238.	2.6	4
137	Adult Prepuceplasty: Comparison of Outcomes of Standard Prepuceplasty and Foreskin Z-plasty. Urology, 2012, 80, 946-950.e1.	1.0	3
138	Translational research will fail without surgical leadership: SCOTRRCC a successful surgeon-led Nationwide translational research infrastructure in renal cancer. Journal of the Royal College of Surgeons of Edinburgh, 2015, 13, 181-186.	1.8	3
139	Striated Muscle in Radical Prostatectomy Specimens: A Marker of Apical Dissection Quality and an Independent Predictor of Urinary Continence after Endoscopic Extraperitoneal Radical Prostatectomy. Urologia Internationalis, 2017, 98, 71-78.	1.3	3
140	The COVID Stones Collaborative: How has the Management of Ureteric Stones Changed During and After the COVID-19 Pandemic? Rationale and Study Protocol. Journal of Endoluminal Endourology, 2020, 3, e22-e28.	0.2	3
141	Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants for Applied Research, 2018, 6, 1-528.	1.0	3
142	Risk prediction models for symptomatic patients with bladder and kidney cancer: a systematic review. British Journal of General Practice, 2022, 72, e11-e18.	1.4	3
143	Predicting cancer outcomes after resection of high-risk RCC. Nature Reviews Urology, 2022, 19, 257-258.	3.8	3
144	Controversial Cases in Endourology. Journal of Endourology, 2006, 20, 612-615.	2.1	2

#	ARTICLE	IF	CITATIONS
145	Multidisciplinary urological engagement in translational renal cancer research. BJU International, 2014, 114, 474-475.	2.5	2
146	Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome. Cellular Oncology (Dordrecht), 2017, 40, 293-297.	4.4	2
147	Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights. Journal of Clinical Oncology, 2017, 35, 3895-3897.	1.6	2
148	Expert Elicitation to Inform a Cost-Effectiveness Analysis of Screening for Renal Cancer. Value in Health, 2019, 22, 981-987.	0.3	2
149	Disagreement in risk groups for metastatic renal cancer. Nature Reviews Urology, 2019, 16, 332-333.	3.8	2
150	The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro. Biology, 2020, 9, 74.	2.8	2
151	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. World Journal of Urology, 2021, 39, 3823-3831.	2.2	2
152	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. Contemporary Clinical Trials, 2021, 108, 106481.	1.8	2
153	Computerized Image Analysis of Tumor Cell Nuclear Morphology Can Improve Patient Selection for Clinical Trials in Localized Clear Cell Renal Cell Carcinoma. Journal of Pathology Informatics, 2020, 11, 35.	1.7	2
154	Real world outcomes of biopsy-proven oncocytic neoplasm of the kidney managed by surveillance. BJUI Compass, 0, , .	1.3	2
155	Re: Clinical Validation of a Targeted Methylation-based Multi-cancer Early Detection Test Using an Independent Validation Set. European Urology, 2022, 82, 442-443.	1.9	2
156	RESULTS OF A DEFINITIVE STUDY ARE NEEDED TO PROVIDE GUIDANCE ON THE TREATMENT OF PATIENTS WITH SCREEN-DETECTED, 'LOW-GRADE' PROSTATE CANCER. BJU International, 2006, 98, 944-945.	2.5	1
157	The Development of Prognostic and Predictive Biomarkers in Renal Cell Cancer Are Not One and the Same Thing. European Urology, 2015, 67, 21-22.	1.9	1
158	Management of a Renal Mass in a Solitary Kidney: To Freeze or To Cut?. European Urology, 2018, 73, 260-261.	1.9	1
159	Improving patient-clinician communication following nephrectomy in renal cell carcinoma: Development, content validation and pilot testing of a conversation aid tool. Patient Education and Counseling, 2021, 104, 99-108.	2.2	1
160	Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials. British Journal of Cancer, 2022, 126, 204-210.	6.4	1
161	Re: Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response. European Urology, 2008, 53, 1085.	1.9	0
162	Partial nephrectomy versus thermal ablation for clinical T1 renal tumours. Annals of Translational Medicine, 2019, 7, S363-S363.	1.7	0

#	ARTICLE	IF	CITATIONS
163	Immunohistochemistry as a tool for screening rare renal cancers. Annals of Translational Medicine, 2019, 7, S314-S314.	1.7	0
164	Re: Transcriptomic Signatures Related to the Obesity Paradox in Patients with Clear Cell Renal Cell Carcinoma: A Cohort Study. European Urology, 2020, 77, 656-657.	1.9	0